Literature DB >> 62037

Measles virus infection and multiple sclerosis: serological studies.

W Cendrowski, I Polna, K Nowicka.   

Abstract

In 159 patients out of 161 with multiple sclerosis (MS), a significant rise in the level of measles hemagglutination inhibition (HI) antibody was found in the serum and in 92 MS patients the occurrence of measles HI antibody in the CSF was significantly more frequent. MS patients showed CSF humoral response against measles virus by neutralizing test (NV) (76%) more often than by hemagglutination test (37%). CSF FA antibody was found in 60%. In the serum of MS patients the presence of NV, HAd, FA, and GP-RNP was observed. 87% of MS patients showed lowered serum: CSF NV or HI antibody ratios and 78% had a diminished FA antibody ratio. Longitudinal study of serum HI measles virus antibody showed no substantial changes over longer period of the disease. Higher CSF measles antibody titer was found in more disabled patients with a malignant course of the disease (P less than 0.001). It is concluded that either persistent infection with proviruses or nonspecific stimulation of certain clones in individuals with genetic susceptibility provides for an excessive synthesis of humoral viral antibodies in MS.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 62037     DOI: 10.1007/BF00316278

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  23 in total

1.  INFECTION AND IMMUNIZATION IN MULTIPLE SCLEROSIS.

Authors:  W A SIBLEY; J M FOLEY
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

2.  Virus antibody levels in serum specimens from patients with optic neuritis and from matched controls;.

Authors:  E Nikoskelainen; J Nikoskelainen; A A Salmi; P E Halonen
Journal:  Acta Neurol Scand       Date:  1975-05       Impact factor: 3.209

3.  Multiple sclerosis and childhood infections.

Authors:  M Alter; W Cendrowski
Journal:  Neurology       Date:  1976-03       Impact factor: 9.910

4.  Antibody levels to parainfluenza, herpes simplex, varicella-zoster, cytomegalo virus, and measles virus in patients with connective tissue diseases.

Authors:  J L Kalliomäki; P Halonen
Journal:  Ann Rheum Dis       Date:  1972-05       Impact factor: 19.103

5.  Measles and multiple sclerosis.

Authors:  E Norrby; B Vandvik
Journal:  Proc R Soc Med       Date:  1974-11

6.  Preliminary report: hemagglutination inhibition measles antibody in the cerebrospinal fluid of patients with multiple sclerosis.

Authors:  W Cendrowski; I Polna; K Niedzielska
Journal:  Z Neurol       Date:  1972-12-29

7.  Histocompatibility determinants in multiple sclerosis.

Authors:  C Jersild; B Dupont; T Fog; P J Platz; A Svejgaard
Journal:  Transplant Rev       Date:  1975

8.  Measles virus antibodies in serum and cerebrospinal fluid in patients with multiple sclerosis and other neurological disorders, with special reference to measles antibody synthesis within the central nervous system.

Authors:  B Vandvik; M Degré
Journal:  J Neurol Sci       Date:  1975-02       Impact factor: 3.181

9.  Comparison of antibodies against different viruses in cerebrospinal fluid and serum samples from patients with multiple sclerosis.

Authors:  E Norrby; H Link; J E Olsson; M Panelius; A Salmi; B Vandvik
Journal:  Infect Immun       Date:  1974-10       Impact factor: 3.441

10.  Serum measles antibodies in multiple sclerosis.

Authors:  W Cendrowski; I Polna; K Niedzielska
Journal:  J Neurol Neurosurg Psychiatry       Date:  1973-02       Impact factor: 10.154

View more
  2 in total

1.  Measles antibodies and kappa-lambda light chain distribution in immunoglobulins of patients affected with multiple sclerosis.

Authors:  F Bollengier; A Mahler
Journal:  J Neurol       Date:  1979-03-22       Impact factor: 4.849

2.  An unusual form of measles meningoencephalitis. A report of two cases.

Authors:  I Derakhshan; A Shafii; J Lotfi; K Abbassioun; J J Scillian
Journal:  J Neurol       Date:  1979-09       Impact factor: 4.849

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.